drugs
Brexit Health Alliance warns of UK at back of the medicine queue
January 29, 2018Medical Communications, Sales and Marketing biotech, brexit, drugs, pharma, pharmaceutical
The Brexit Health Alliance (BHA) has cautioned that unless a favourable deal is struck, the UK could end Brexit negotiations …
Sanofi swoops for Ablynx in $4.8bn deal
January 29, 2018Sales and Marketing Ablynx, Sanofi, biotech, drugs, pharma, pharmaceutical
Sanofi has moved quickly to tie up a deal with Ablynx for $4.8 billion, when it looked more likely that …
NICE urges curbing the use of antibiotics for sore throats
January 26, 2018Medical Communications Antibiotics, NICE, biotech, drugs, pharma, pharmaceutical
In a study published by the BMJ a few years ago, it was found that antibiotics were prescribed in 60% …
AZ’s triple therapy inhaler hits 8 out of 9 endpoints
January 26, 2018Medical Communications, Research and Development AstraZeneca, COPD, biotech, drugs, pharma, pharmaceutical
AstraZeneca has made a brief announcement that its triple therapy inhaler manage to successfully hit eight of nine primary endpoints …
Biogen announces acquisition along with financials, but it’s tiny
January 26, 2018Medical Communications, Sales and Marketing Biogen, Karyopharm, biotech, drugs, pharma, pharmaceutical
Biogen is one those companies, like Sanofi until its recent Bioverativ acquisition, that has real pressure to make a big …
Senescent cell findings provides Parkinson’s treatment clue
January 25, 2018Research and Development Alzheimer's, biotech, drugs, pharma, pharmaceutical
Senescent cells are the dormant state that cells shift to in response to certain stressors, it is thought that they …
Amyloid pathway doubts after latest Alzheimer’s failure
January 25, 2018Research and Development Alzheimer's, biotech, drugs, pharma, pharmaceutical
There has been another drug failure in a large Phase 3 that once again crushes a hope for a possible …
GW Pharma boasts new positive data, readying for approval
January 25, 2018Research and Development GW Pharma, biotech, drugs, pharma, pharmaceutical
The latest data from GW Pharma is about as conclusively positive as you can usually hope to get with a …
Celgene confirms rumours, with $9bn deal for Juno
January 22, 2018Manufacturing and Production, Sales and Marketing CAR-T, Celgene, biotech, drugs, juno therapeutics, pharma, pharmaceutical
It seems like 2018 may well be the year for M&A that everyone had expected, as two major deals on …
Biogen’s Spinraza to go before NICE
January 22, 2018Sales and Marketing Biogen, Spinraza, biotech, drugs, pharma, pharmaceutical
Biogen received marketing approval from the European Commission for Spinraza (nusinersen), its treatment for spinal muscular atrophy (SMA), in May …
Court fines Dr Reddy’s for improperly packaging products
January 22, 2018Sales and Marketing Dr Reddy's, biotech, drugs, pharma, pharmaceutical
On 18 December 2017, the District of New Jersey filed a complaint against Dr. Reddy’s Laboratories for failing to comply …
Sanofi finally seals big deal with $11.6bn for Bioverativ
January 22, 2018Sales and Marketing Sanofi, biotech, bioverativ, drugs, pharma, pharmaceutical
Sanofi interest in making a big acquisition has been clear for the last few years and its struggles to solidify …
Novartis enters biosimilar agreement with Biocon
January 19, 2018Medical Communications, Sales and Marketing Biocon, Novartis, Sandoz, biosimilars, biotech, drugs, pharma, pharmaceutical
Novartis’ Sandoz unit had already staked a claim to being one of the leaders in the developing biosimilar market and …
Gilead aims to claim edge with Pfizer CAR-T combo
January 18, 2018Medical Communications, Research and Development Gilead, Kite, Yescarta, biotech, drugs, pharma, pharmaceutical
Although those in pharma often dislike any references to drugs competing with each other for market as in a ‘race’, …
Riding the wave: The FDA and real world evidence
January 18, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biotech, drugs, pharma, pharmaceutical, real world evidence
Following on from this week’s earlier piece on real world evidence, Jacqueline Corrigan-Curay, Director of CDER’s Office of Medical Policy at the FDA, …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
